Jason Harris | Authors


High Disease Control Rate Achieved With Belzutifan and Cabozantinib in ccRCC

February 15, 2021

The addition of the oral hypoxia-inducible factor 2α inhibitor belzutifan to cabozantinib led to disease control in a majority of patients with previously treated advanced clear cell renal cell carcinoma, according to preliminary results from a phase 2 trial presented at the 2021 Genitourinary Cancers Symposium.

Adjuvant Nivolumab Extends Disease-Free Survival in Muscle-Invasive Urothelial Carcinoma

February 13, 2021

Results from the phase 3 CheckMate-274 trial showed that nivolumab following surgery improved disease-free survival compared with placebo for patients with muscle-invasive urothelial carcinoma, according a presentation given during the 2021 ASCO Genitourinary Cancer Symposium.